Avenue Therapeutics (ATXI) Tops Q3 EPS by 34c
Avenue Therapeutics (NASDAQ: ATXI) reported Q3 EPS of $0.06, $0.34 better than the analyst estimate of ($0.28).
For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.
Avenue Therapeutics (NASDAQ: ATXI) reported Q3 EPS of $0.06, $0.34 better than the analyst estimate of ($0.28).
For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.